7 completed, 2 terminated, 2 unknown, 1 active not recruiting. 12 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 7, Terminated 2, Unknown 2, Active not recruiting 1 |
| Phase 2 | 2 | Terminated 2 |
Follow Motion Sickness: new trials by email Literature Review of Motion Sickness trials Research Report on Motion Sickness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness Tradipitant, Placebo - Motion Sickness | Phase 3 | Completed | Vanda Pharmaceuticals | 316 | 2023-09-09 | 2025-04-04 |
| Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Tradipitant - Motion Sickness | Phase 3 | Active not recruiting | Vanda Pharmaceuticals | 705 | 2023-02-27 | 2026-04-16 |
| Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion DPI-386 Nasal Gel, Placebo - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 503 | 2022-08-23 | 2023-03-21 |
| Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness Tradipitant, Placebo - Motion Sickness | Phase 3 | Completed | Vanda Pharmaceuticals | 366 | 2021-11-15 | 2024-12-11 |
| Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion DPI-386 Nasal Gel, Placebo - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 140 | 2021-06-14 | 2021-09-17 |
| Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness DPI-386 Nasal Gel, Placebos - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 102 | 2019-06-09 | 2019-12-03 |
| Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects Scopolamine, Placebo Nasal Gel - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 98 | 2019-06-07 | 2023-05-06 |
| The Prevention and Treatment of Nausea Associated With Motion Sickness Scopolamine Nasal Gel, Placebo - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 300 | 2019-04-26 | 2019-12-03 |
| Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness scopolamine HBr, Transdermal Scopolamine - Motion Sickness | Phase 3 | Unknown | Repurposed Therapeutics, Inc. | 300 | 2019-04-22 | 2020-02-17 |
| Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch - Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness | Phase 3 | Unknown | Naval Aeromedical Research Unit, Dayton | 320 | 2019-04-01 | 2019-04-19 |
| DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop® - Motion Sickness | Phase 2 / Phase 3 | Terminated | Repurposed Therapeutics, Inc. | 23 | 2018-06-29 | 2020-01-07 |
| Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray Scopolamine, Placebo - Motion Sickness | Phase 2 / Phase 3 | Terminated | Repurposed Therapeutics, Inc. | 63 | 2014-06-01 | 2018-01-17 |
Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (12)
Scopolamine (7) · Transdermal Patch (1) · tyramine-deoxysorbitol (1)
Repurposed Therapeutics, Inc. (8) · Vanda Pharmaceuticals (3) · Naval Aeromedical Research Unit, Dayton (1)
United States (12)
David Helton (4) · David R Helton (2) · Dave Helton (1) · Willliam J Becker, Phd (1)